26CA.F IMMUNITYBIO INC. DL-0001

Healthcare Biotechnology Frankfurt Exchange
6.03 EUR
Close of Nov 11, 2026
1.70 10.40
Market cap
EUR 6.41B
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 26CA.F undervalued?

Graham number

The Graham number of IMMUNITYBIO INC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IMMUNITYBIO INC. DL-0001 fundamental analysis

No fundamental analysis for IMMUNITYBIO INC. DL-0001 yet.

IMMUNITYBIO INC. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IMMUNITYBIO INC. DL-0001

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic ag…

Full company profile